Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

the SAKK and the German CML Study Group, for; Hehlmann, Rüdiger; Lauseker, Michael; Saußele, Susanne; Pfirrmann, Markus; W. Krause, Stefan; Kolb, Hans‐Jochem; Neubauer, Andreas; K. Hossfeld, Dieter; Nerl, C.; Gratwohl, Aloïs; M. Baerlocher, Gabriela; Heim, Dominik; H. Brümmendorf, Tim; Fabarius, Alice; Haferlach, Claudia; Schlegelberger, Brigitte; Müller, Marcus; Jeromin, Sabine; Proetel, Ulrike; Kohlbrenner, Katharina; Voskanyan, Astghik; Rinaldetti, Sébastien; Seifarth, Wolfgang; Spieß, Birgit; Balleisen, Leopold; Goebeler, M-E; Hänel, Mathias; D. Ho, Anthony; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Kremers, Stephan; Burchert, Andreas; Kneba, Michael; Stegelmann, Frank; Köhne, Claus-Henning; W. Lindemann, H.; F. Waller, Cornelius; Pfreundschuh, M.; Spiekermann, Karsten; E. Berdel, Wolfgang; Müller, Lothar; Edinger, Matthias; Mayer, Jiřı́; W. Beelen, Dietrich; Bentz, Martin; Link, Hartmut; Hertenstein, Bernd; J. Fuchs, Roland; Wernli, Martin; Schlegel, Frank; Schlag, Rudolf; de Wit, Maike; Trümper, Lorenz; Hebart, Holger; Hahn, Markus; Thomalla, Jörg; Scheid, Christof; Schafhausen, Philippe; Verbeek, Walter; J. Eckart, Michael; Gaßmann, W.; Pezzutto, Antonio; Schenk, Michael; Brossart, Peter; Geer, Thomas; Bildat, Stephan; Schäfer, E.; Hochhaus, Andreas; Hasford, Joerg

doi:10.1038/leu.2017.253

Public

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Published in Leukemia • Aug 14, 2017

Authors:

for the SAKK and the German CML Study Group

Rüdiger Hehlmann

Michael Lauseker

Abstract

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 ...

Subject

Imatinib

Myeloid leukemia

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!